We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.

Inflammatory Bowel Diseases

40% of Inflammatory Bowel Disease patients relapse every year.1,2,3

40% of Inflammatory Bowel Disease (IBD) patients relapse every year.1,2,3 52% of Ulcerative Colitis (UC)  patients who have an active disease are included in this statistic.1,2,3 As a result, 187,000 hospitalizations, per year, take place, specifically for Crohn's disease (CD).4 Current disease assessment techniques are suboptimal and do not accurately predict relapse.

Cellvizio® Clinical Value 

With Cellvizio, physicians provide an early prediction of relapse within the next 12 months, as well as relevant clinical outcomes that require hospitalization or surgery for IBD patients.5,6 Physicians are also able to now monitor treatment to differentiate responders from non-responders.7

Untitled design (7).png

Cellvizio mucosal assessment using Cellvizio® ColoFlexTM UHD Miniprobe 

Healthy Mucosa

Cellvizio® provides real-time in vivo imaging 

Ulcerative colitis

Cellvizio® provides real-time in vivo imaging 

Dysplastic Mucosa

Cellvizio® provides real-time in vivo imaging 

Patient Management

With Cellvizio, patient management is improved because physicians can now differentiate between diagnoses of IBD.10 Relapse is predicted, which allows for an extended remission period and flare ups are also assessed, which confirms mucosal inflammation. 5,11
The treatment then improves because physicians can assess mucosal barrier function for predicting improved long-term patient outcome.7
In the case of cancer, physicians improve care by being able to characterize suspicious lesions.12

IBD Patient management.png

"Cellvizio is the only technology that allows us to see functional healing, and it is worth having this information as it is the best determinant of outcome for my IBD patients"
Prof. Dr. T. Rath, University Hospital Erlangen

1. Data from Crohn’s & Colitis Foundation of America. 2014.
2. Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet, 2017.
3. Burisch J. et al. The burden of inflammatory bowel disease in Europe. Journal of Crohn’s and Colitis, 2013.
4. CDC/NCHS national hospital discharge survey: United States, 2010. Centers for Disease Control and Prevention website. www. cdc.gov/nchs/data/nhds/10Detaileddiagnosesprocedures/ 2010det10_numberalldiagnoses.pdf. (PDF, 1,506 KB)* Accessed April 2019.
5. Turcotte JF. et al. Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease, Clin tranfl Gastroenterol, 2012.
6. Tontini GE. et al. Prediction of clinical outcomes in Crohn’s disease by using confocal laser endomicroscopy: results from a prospective multicenter study. Gastrointestinal Endoscopy. 2017.
7. Hundorfean G. et al. Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients. Inflamm Bowel Dis, 2017.
8. Shahid M.W. et al. Diagnostic Accuracy of probe based Confocal Laser Endomicroscopy in Detecting Residual Colorectal Neoplasia after EMR: A prospective Study. Gastrointestinal Endoscopy, 2012.
9. Neumann H. et al. Prospective evaluation of the learning curve of confocal laser endomicroscopy in patients with IBD, Histol Histopathol, 2011.
10. Queneherve L. et al. Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases. Gastrointest Endosc, (Epub), 2018.
11. Maione F. et al. Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. Tech Coloproctol, (Epub), 2017.
12. Lord R. et al. Colonic lesion characterization in inflammatory bowel disease: A systematic review and metaanalysis. World J Gastroenterol, 2018. 

Find out more by downloading the
Cellvizio Brochure

Discover